Maligned Canadian cannabis producer CannTrust Holdings (NYSE:CTST,TSX:TRST) is facing a class-action lawsuit update.

On Monday (February 3), Henein Hutchison, speaking for a group of Ontario-based law firms, issued a statement claiming that the Ontario Superior Court of Justice has confirmed that the group can carry on with a proposed securities class action targeting the marijuana company.

The legal action is tied to CannTrust’s improper cannabis growing operations, which were discovered by regulators in July 2019. The misstep led to an eventual license suspension for the company and the damage to its reputation caused to the larger Canadian cannabis market to take a hit.

Shares of CannTrust fell in both New York and Toronto during Monday’s session. The company finished the first trading day of the week priced at US$1.04 and C$1.37.

In the pre-market trading portion of Tuesday (February 4), the company was already down an additional almost 4 percent on the New York Stock Exchange. However, just after the official start of the session, it bounced back with a 2.92 percent increase in Toronto and a 1.44 percent marginal jump in New York.

Since the original illegitimate growing discovery, which brought the dismissal of the firm’s former CEO and of its co-founder, shares of CannTrust have dropped in value dramatically by over 70 percent in both New York and Toronto.

stock chart for CannTrust Holdings

“Cases like this show the power of class actions to bring access to justice to individuals who place their savings at risk in the stock markets,” Dimitri Lascaris, a lawyer working within the group representing the investors raising the suit, said in a statement.

Marie Henein, another lawyer working on the lawsuit, said the case will be brought in front of the courts “at the earliest opportunity.”

In an emailed statement, a CannTrust spokesperson declined to comment for this story.

In its most recent mandated bi-weekly update to investors, CannTrust made no mention of the progress for the class-action suit. The company signaled it still has a cash balance of nearly C$175 million.

The legal action comes from CannTrust investors who bought shares of the company between June 1, 2018, and September 17, 2019, according to the parameters of the suit, in addition to investors who participated in a prospectus offering from the company in May 2019.

In addition to CannTrust, the suit also includes the underwriters of the CannTrust offering: Merrill Lynch Canada, Citigroup Global Markets Canada, Credit Suisse Securities (Canada), RBC Dominion Securities, Jefferies Securities and Canaccord Genuity.

The raise was designed to secure CannTrust with US$170 million in gross proceeds thanks to the sale of just over 5.4 million shares.

Tax audit and advisory firm KPMG is also included as a defendant in this case, given its role as CannTrust’s auditor.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here:

Keep reading... Show less